Unlocking the Potential: Amarin’s Reduce-It Data at ACC 23 WCC Demonstrates the Life-Saving Benefits of Vascepa/Vazkepa in High-Risk Patients with Recent Acute Coronary Syndrome Events
Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without Increased Bleeding Analysis Builds on Consistently Demonstrated Positive Outcomes for VASCEPA/VAZKEPA Across Sub-Populations in REDUCE-IT, Including in Patients with Prior Myocardial Infarction (MI), Prior Revascularization, Prior Peripheral Arterial Disease (PAD) and Diabetes…